• Recruiting

NCT04613557: Phase 1: Safety, Activity and Cell Kinetics of CYAD-211 in RRMM Myeloma (IMMUNICY-1)

Updated: May 25


NCT04613557: Phase 1: Safety, Activity and Cell Kinetics of CYAD-211 in Patients With Relapsed or Refractory Multiple Myeloma (IMMUNICY-1)

cyad 211

Safety, Activity and Cell Kinetics of CYAD-211 in Patients With Relapsed or Refractory Multiple Myeloma (IMMUNICY-1)


The purpose of the IMMUNICY-1 study is to assess the safety, activity and cell kinetics of CYAD-211 in adults with relapsed or refractory multiple myeloma after a lymphodepletion regimen with fludarabine and/or cyclophosphamide


Sponsor

Celyad Oncology SA

 

ClinicalTrials.gov Identifier: NCT04613557


Official Title: Open-label Phase I, Multi-center Study to Determine the Recommended Dose of CYAD-211 After a Non-myeloablative Preconditioning Chemotherapy in Multiple Myeloma Patients With Relapsed or Refractory Disease


First Posted : November 3, 2020


Click here to see details on ClinicalTrials.gov

 

Biological: CYAD-211

Drug: Endoxan

Drug: Fludara

 

CYAD 211

Allogeneic shRNA-based Anti-BCMA CAR T-cells CYAD-211 (Code C176885)

Allogeneic shRNA-based Anti-BCMA CAR T-cells CYAD-211

Allogeneic shRNA-based Anti-BCMA CAR-T Cells CYAD-211

CYAD 211

CYAD-211

CYAD211

 

Locations

United States, Florida

United States, New York

Europe

Belgium



Posts Archive